DCM
RLMD icon

Driehaus Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Driehaus Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Hold
2,132,053
– – 0.09% 254
2026
Q1 		$14.8M Buy
2,132,053
+252,047
+13% +$1.19M 0.11% 239
2025
Q4 		$9.08M Buy
1,880,006
+1,140,000
+154% +$3.82M 0.06% 277
2025
Q3 		$1.49M Hold
740,006
– – 0.01% 360
2025
Q2 		$444K Buy
+740,006
New +$380K ﹤0.01% 391

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Driehaus Capital Management's RLMD Position: Q2 2026 in Review

Driehaus Capital Management held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 2,132,053 shares worth $14.8M. The position accounts for 0.09% of the portfolio, ranked #254.

Driehaus Capital Management first reported a position in RLMD in Q2 2025 and has held it in 5 quarters since. The position peaked at $14.8M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Driehaus Capital Management held 2,132,053 shares of Relmada Therapeutics worth $14.8M as of Q2 2026.
  • Driehaus Capital Management left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 0.09% of Driehaus Capital Management's portfolio in Q2 2026, its #254 holding.
  • Driehaus Capital Management first reported a position in Relmada Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Driehaus Capital Management's Relmada Therapeutics position peaked at $14.8M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.